Medicyte Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-06-2024
- Paid Up Capital ₹ 0.10 M
as on 14-06-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.75 M
as on 14-06-2024
- Revenue 37.20%
(FY 2023)
- Profit -66.92%
(FY 2023)
- Ebitda 2.60%
(FY 2023)
- Net Worth 10.93%
(FY 2023)
- Total Assets 155.44%
(FY 2023)
About Medicyte Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.75 M.
Shirish Chavan, Sudhir Marne, Shailesh Gharat, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC283228
- Company No.
283228
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Navi Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medicyte Pharmaceutical?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shirish Chavan  | Director | 01-Dec-2020 | Current |
| Sudhir Marne | Director | 04-Jul-2016 | Current |
| Shailesh Gharat | Director | 04-Jul-2016 | Current |
| Ashok Tetgure | Director | 04-Jul-2016 | Current |
Financial Performance and Corporate Structure Insights of Medicyte Pharmaceutical.
Medicyte Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 37.2% increase. The company also saw a substantial fall in profitability, with a 66.92% decrease in profit. The company's net worth Soared by an impressive increase of 10.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medicyte Pharmaceutical?
In 2023, Medicyte Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Feb 2023 | ₹3.95 M | Open |
Axis Bank Limited Creation Date: 09 Mar 2022 | ₹3.80 M | Open |
How Many Employees Work at Medicyte Pharmaceutical?
Unlock and access historical data on people associated with Medicyte Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medicyte Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medicyte Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
